Rubicon Research Limited announced key decisions from its Board of Directors meeting held on February 3, 2026. The board approved the appointment of Dr. Pradnya Saravade as an Additional-Independent Woman Director for a three-year term, effective February 3, 2026, to February 2, 2029, subject to shareholder approval. Dr. Saravade brings extensive experience from her career in the Indian Police Service, including roles in governance, administration, and investigations. The board also noted the resignation of Mr. Anand Agarwal as a Non-Executive Director, effective at the close of business on February 3, 2026. He cited other pressing commitments for his departure. Furthermore, M/s. BNP & Associates has been approved and recommended as the company's Secretarial Auditor for FY 2025-26 and the subsequent four years, until FY 2029-30, pending member approval. BNP & Associates is a peer-reviewed firm with significant experience in secretarial audits and corporate advisory services. In a significant strategic move, the board granted in-principle approval for the merger of KIA Health Tech Private Limited, a wholly-owned subsidiary, with Rubicon Research Limited. This merger is subject to the approval of the scheme of arrangement, regulatory approvals, and other formalities. The rationale for the merger is to achieve operational synergies. The net-worth of KIA Health Tech as of March 31, 2025, was ₹815.80 Lakhs, with nil revenue, while Rubicon Research had a net-worth of ₹66,778.57 Lakhs and revenue of ₹1,09,352.40 Lakhs. No cash consideration will be involved, and the shareholding pattern of Rubicon Research will remain unchanged.
